Merck (MRK) announced that a phase II/III study has been initiated on its CDH6-directed DXd antibody-drug conjugate, raludotatug deruxtecan (R-DXd), in patients with platinum-resistant ovarian cancer. The first patient has been dosed in the phase II/III study called REJOICE-Ovarian01. Merck is developing R-DXd in partnership with Japan’s Daiichi Sankyo.The initiation of the REJOICE-Ovarian01 study is based on data from the ongoing phase I study in which R-DXd showed promising activity in patients with advan ...

Sundry Photography One of the biggest pharmaceutical stocks by market capitalization, Merck & Co., Inc. (NYSE:MRK) has had a good first quarter at the stock markets in 2024. Its price is up by over 20% after a forgettable 2023 that saw it end the year essentially flat, supported by approvals for its treatments as well as its final quarter (Q4 2023) and full-year 2023 results. Supportive fundamentals might be a necessary condition for a stock’s consistent success in the markets, but they aren’t sufficien ...

GERMANY - 2024/02/16: In this photo illustration, a Pfizer, Inc. logo seen displayed on a tablet. ... [+] (Photo Illustration by Igor Golovnov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesGiven its attractive valuation, we believe Pfizer stock (NYSE: PFE) is a better pick than its peer — Merck stock (NYSE: MRK). MRK trades at a higher valuation multiple of 5.6x revenues vs. 2.7x for PFE, due to its superior revenue growth over the last year and a better financial position ...

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scores?The Z ...

Merck (MRK) announced that the phase III KEYLYNK-006 study, evaluating the combination of its blockbuster drugs Keytruda and Lynparza in certain non-small cell lung cancer (NSCLC) patients, failed to meet its primary endpoints.The KEYLYNK-006 study evaluated Keytruda, combined with Lynparza as maintenance therapy, for the first-line treatment for patients with metastatic non-squamous NSCLC with no EGFR, ALK or ROS1 genomic tumor aberrations. Patients in the control group received pemetrexed chemotherapy ins ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive data from multiple Phase 3 studies evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine, at the 13th Meeting of the International Society of Pneumonia and Pneumococcal Diseases (ISPPD) in Cape Town, South Africa. Across the clinical studies presented, V116 was shown to be immunogenic for all 21 serotypes covered by the vaccine in ...

Cutting edge & AI solution for continuous and precise monitoring of individual swine weight HOD HASHARON, Israel, March 15, 2024 /PRNewswire/ -- FarmSee, a pioneer in camera-based Artificial Intelligence ("AI") solutions for swine monitoring and production optimization, is excited to announce a strategic collaboration with MSD Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK).  MSD Animal Health, a biopharmaceuticals and technology solutions company, has participated in FarmSee's ...

RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the Phase 3 KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating KEYTRUDA, Merck’s anti-PD-1 therapy, in combination with chemoradiotherapy (CRT) met its primary endpoint of overall survival (OS) for the treatment of newly diagnosed patients with high-risk locally advanced cervical cancer. At a pre-specified interim analysis conducted by an independent Data Monitoring ...

In the latest trading session, Merck (MRK) closed at $120.51, marking a -1.35% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.29% for the day. At the same time, the Dow lost 0.35%, and the tech-heavy Nasdaq lost 0.3%.The the stock of pharmaceutical company has fallen by 2.91% in the past month, lagging the Medical sector's gain of 3.72% and the S&P 500's gain of 4.42%.The investment community will be paying close attention to the earnings performance of Merck i ...

The most recent trading session ended with Merck (MRK) standing at $122.16, reflecting a -0.41% shift from the previouse trading day's closing. This change lagged the S&P 500's 0.19% loss on the day. Elsewhere, the Dow saw an upswing of 0.1%, while the tech-heavy Nasdaq depreciated by 0.54%.The pharmaceutical company's shares have seen a decrease of 2.21% over the last month, not keeping up with the Medical sector's gain of 2.91% and the S&P 500's gain of 3.18%.The investment community will be paying close ...